Probiotics and clinical effects: Is the number what counts?

Journal of Chemotherapy

Volumn 25, Issue 4, 2013, Pages 194-212

  Bertazzoni, Elisa ^a   Donelli, Gianfranco ^b   Midtvedt, Tore ^c   Nicoli, Jacques ^d   Sanz, Yolanda ^e  

^a Pharmacology Section   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c KAROLINSKA INSTITUTE   (Sweden)

^d FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^e INSTITUTO DE AGROQUÍMICA Y TECNOLOGÍA DE ALIMENTOS CSIC   (Spain)

Author keywords

Clinical trials; Effective dose; Health claims; Probiotics

Indexed keywords

ANTIBIOTIC AGENT; BALSALAZIDE; INFLORAN; INTERLEUKIN 10; INTERLEUKIN 4; LACTEOL FORT; LACTINEX; MESALAZINE; MUTAFLOR; PLACEBO; PROBIOTIC AGENT; UNCLASSIFIED DRUG;

ANTIBIOTIC ASSOCIATED DIARRHEA; ATOPIC DERMATITIS; BACTERIAL COLONIZATION; BACTERIAL SURVIVAL; CLOSTRIDIUM DIFFICILE INFECTION; COLONY FORMING UNIT; CROHN DISEASE; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ECZEMA; FECES ANALYSIS; HUMAN; ILEITIS; IRRITABLE COLON; LOW DRUG DOSE; META ANALYSIS (TOPIC); MICROBIAL VIABILITY; MORTALITY; NECROTIZING ENTEROCOLITIS; PHAGOCYTOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SHELF LIFE; SINGLE DRUG DOSE; TREATMENT DURATION; ULCERATIVE COLITIS; BACTERIAL COUNT; BIOAVAILABILITY; ENTEROPATHY; EVIDENCE BASED MEDICINE; GASTROINTESTINAL TRACT; IMMUNOMODULATION; METABOLISM; MICROBIOLOGY;

BIOLOGICAL AVAILABILITY; COLONY COUNT, MICROBIAL; DERMATITIS, ATOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; EVIDENCE-BASED MEDICINE; GASTROINTESTINAL TRACT; HUMANS; IMMUNOMODULATION; INTESTINAL DISEASES; MICROBIAL VIABILITY; PROBIOTICS;

EID: 84880944639     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947813Y.0000000078     Document Type: Review

References (175)

1. Bibel D. Elie Metchnikof's bacillus of long life. ASM News. 1988;54:661-5.
2. Tissier H. Recherches sur la flore intestinale normale et pathologique du nourrisson [dissertation]. Paris: University of Paris; 1900.
3. Hooper LV, Midtvedt T, Gordon JI. How host-microbial interactions shape the nutrient environment of the mammalian intestine. Annu Rev Nutr. 2002;22:283-307.
4. Guarner F. Probiotics and chronic gastrointestinal disease. Prebiot Probiot Sci Technol. 2009;22:949-75.
5. Holzapfel WH, Haberer P, Snel J, Schillinger U, Huis in't Veld JH. Overview of gut flora and probiotics. Int J Food Microbiol. 1998;41:85-101.
6. Sanders ME. Probiotics: considerations for human health. Nutr Rev. 2003;61:91-9.
7. Wilson M. Microbial inhabitants of humans. Cambridge: Cambridge University Press; 2004.
8. Marteau P, Shanahan F. Basic aspects and pharmacology of probiotics: an overview of pharmacokinetics, mechanisms of action and side-effects. Best Pract Res Clin Gastroenterol. 2003;17:725-40.
9. Vesa T, Pochart P, Marteau P. Pharmacokinetics of Lactobacillus plantarum NCIMB 8826, Lactobacillus fermen- tum KLD, and Lactococcus lactis MG 1363 in the human gastrointestinal tract. Aliment Pharmacol Ther. 2000;14:823-8.
10. Donnet-Hughes A, Rochat F, Serrant P, Aeschlimann JM, Schiffrin EJ. Modulation of nonspecific mechanisms of defense by lactic acid bacteria: effective dose. J Dairy Sci. 1999;82(5):863-9.
11. Christensen HR, Larsen CN, Kaestel P, Rosholm LB, Sternberg C, Michaelsen KF, et al. Immunomodulating potential of supplementation with probiotics: a dose-response study in healthy young adults. FEMS Immunol Med Microb. 2006;47:380-90.
12. Oozeer R, Leplingard A, Mater DD, Mogenet A, Michelin R, Seksek I, et al. Survival of Lactobacillus casei in the human digestive tract after consumption of fermented milk. Appl Environ Microbiol. 2006;72:5615-7.
13. Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on main-tenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther. 1999;13:1103-8.
14. Czerucka D, Dahan S, Mograbi B, Rossi B, Rampal P. Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells. Infect Immun. 2000;68(10):5998-6004.
15. Ezendam J, van Loveren H. Probiotics: immunomodulation and evaluation of safety and efficacy. Nutr Rev. 2006;64(1):1-14.
16. Servin AL. Antagonistic activities of lactobacilli and bifido-bacteria against microbial pathogens. FEMS Microbiol Rev. 2004;28(4):405-40.
17. Servin AL, Coconnier MH. Adhesion of probiotic strains to the intestinal mucosa and interaction with pathogens. Best Pract Res Clin Gastroenterol. 2003;17(5):741-54.
18. Czerucka D, Rampal P. Experimental effects of Saccharomyces boulardii on diarrheal pathogens. Microbes Infect. 2002;4(7):733-9.
19. Brandão RL, Castro IM, Bambirra EA, Amaral SC, Fietto LG, Tropia MJ, et al. Intracellular signal triggered by cholera toxin in Saccharomyces boulardii and Saccharomyces cerevi-siae. Appl Environ Microbiol. 1998;64(2):564-8.
20. Helwig U, Lammers KM, Rizzello F, Roehleder V, Caramelli E, Gionchetti P, et al. Lactobacilli, bifidobacteria, and E. coli nissle induce pro-and anti-inflammatory cytokines in periph-eral blood mononuclear cells. World J Gastroenterol. 2006;12:5978-86.
21. Pagnini C, Saeed R, Bamias G, Arseneau KO, Pizarro TT, Cominelli F. Probiotics promote gut health through stimula-tion of epithelial innate immunity. Proc Natl Acad Sci USA. 2010;107:454-9.
22. Jobin C. Probiotics and ileitis: could augmentation of TNF/ NFkB activity be the answer? Gut Microbes. 2010;1:196-9.
23. Dai C, Zhao DH, Jiang M. VSL#3 probiotics regulate the intestinal epithelial barrier in vivo and in vitro via the p38 and ERK signaling pathways. Int J Mol Med. 2012;29:202-8.
24. Sonnenburg J.L. Chen CT, Gordon JI. Genomic and metabolic studies of the impact of probiotics on a model gut symbiont and host. Plos Biol. 2006;4:2213-26.
25. Prantera C, Scribano ML. Probiotics and Crohn's disease. Dig Liver Dis. 2002;34(2):S66-7.
26. Bousvaros A, Guandalini S, Baldassano RN, Botelho C, Evans J, Ferry GD, et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis; 2005;11:833-9.
27. Kuisma J, Mentula S, Jarvinen H, Kahri A, Saxelin M, Farkkila M. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther. 2003;17:509-15.
28. Zocco MA, Dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 2006;23:1567-74.
29. Bausserman M, Michail S. The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind rando-mized control trial. J Pediatr. 2005;147(2):197-201.
30. Gawronska A, Dziechciarz P, Horvath A, Szajewska H. A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Aliment Pharmacol Ther. 2007;25:177-84.
31. Szajewska H, Mrukowicz JZ. Use of probiotics in children with acute diarrhea. Paediatr Drugs. 2005;7:111-22.
32. Kataria J, Li N, Wynn J L, Neu J. Probiotic microbes: do they need to be alive to be beneficial? Nutr Rev. 2009;67:546-50.
33. Miyauchi E, Morita H, Tanabe S. Lactobacillus rhamnosus alleviates intestinal barrier dysfunction in part by increasing expression of zonula occludens-1 and myosin light-chain kinase in vivo. J Dairy Sci. 2009;92(6):2400-8.
34. Li N, Russell WM, Douglas-Escobar M, Hauser N, Lopez M, Neu J. Live and heat-killed Lactobacillus rhamnosus GG: effects on proinflammatory and anti-inflammatory cytokines/ chemokines in gastrostomy-fed infant rats. Pediatr Res. 2009;66(2):203-7.
35. Raza S, Graham SM, Allen SJ, Sultana S, Cuevas L, Hart CA. Lactobacillus GG promotes recovery from acute nonbloody diarrhea in Pakistan. Pediatr Infect Dis J. 1995;14(2):107-11.
36. McCartney AL, Wenzhi W, Tannock GW. Molecular analysis of the composition of the bifidobacterial and lactobacillus microflora of humans. Appl Environ Microbiol. 1996;62:4608-13.
37. Sazawal S, Hiremath G, Dhingra U, Malik P, Deb S, Black RE. Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials. Lancet Infect Dis. 2006;6(6):374-82.
38. Dubey AP, Rajeshwari K, Chakravarty A, Famularo G. Use of VSL#3 in the treatment of rotavirus diarrhea in children: preliminary results. J Clin Gastroenterol. 2008;42 Suppl 3 Pt 1:S126-9.
39. Hibberd PL. Probiotics for infections diarrhea and travel's diarrhea - what do we really know? Prebiot Probiot Sci Technol. 2009;22:846-99.
40. Allen SJ, Okoko B, Martinez E, Gregorio G, Dans LF. Probiotics for treating infectious diarrhoea. Cochrane Database Syst Rev. 2004;(2):CD003048.
41. van Niel CW, Feudtner C, Garrison MM, Christakis DA. Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis. Pediatrics. 2002;109:678-84.
42. Guandalini S, Pensabene L, Zikri MA, Dias JA, Casali LB, Hoekstra H, et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhoea: a multicenter European trial. J Pediatr Gastroenterol Nutr. 2000;30(1):54-60.
43. Guarino A, Canani RB, Spagnuolo MI, Albano F, Di Benedetto L. Oral bacterial therapy reduces the duration of symptoms and viral excretion in children with mild diarrhoea. J Pediatr Gastroenterol Nutr. 1997;25(5):516-9.
44. Isolauri E, Kaila M, Mykkanen H, Ling WH, Salminen S. Oral bacteriotherapy for viral gastroenteritis. Dig Dis Sci. 1994:39(12):2595-600.
45. Sugita T, Togawa M. Efficacy of Lactobacillus preparation bioloactis powder in children with rotavirus enteritis. Jpn J Pediatr. 1994;47:2755-62.
46. Allen SJ, Martinez EG, Gregorio GV, Dans LF. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev. 2010;(11):CD003048.
47. Rautanen T, Isolauri E, Salo E, Vesikari T. Management of acute diarrhoea with low osmolarity oral rehydration solu-tions and Lactobacillus strain GG. Arch Dis Child. 1998;79(2):157-160.
48. Johnston BC, Supina AL, Ospina M, Vohra S. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2007;(2):CD004827
49. Johnston BC, Goldenberg JZ, Vandvik PO, Sun X, Guyatt GH. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2011;(11):CD004827.
50. Ruszczyński M, Radzikowski A, Szajewska H. Clinical trial: effectiveness of Lactobacillus rhamnosus (strains E/N, Oxy and Pen) in the prevention of antibiotic-associated diarrhoea in children. Aliment Pharmacol Ther. 2008;28(1):154-61.
51. Szymanski H, Armaska M, Kowalska-Duplaga K, Szajewska H. Bifidobacterium longum PL03, Lactobacillus rhamnosus KL53A, and Lactobacillus plantarum PL02 in the prevention of antibiotic-associated diarrhea in children: a randomized controlled pilot trial. Digestion. 2008;78:13-7.
52. Merenstein DJ, Foster J, D'Amico F. A randomized clinical trial measuring the influence of kefir on antibiotic-associated diarrhea: the measuring the influence of Kefir (MILK) Study. Arch Pediatr Adolesc Med. 2009;163:750-4.
53. Szajewska H, Albrecht P, Topczewska-Cabanek A. Randomized, double-blind, placebo-controlled trial: effect of lactobacillus GG supplementation on Helicobacter pylori eradication rates and side effects during treatment in children. J Pediatr Gastroenterol Nutr. 2009;48:431-6.
54. Videlock EJ, Cremonini F. Meta-analysis: probiotics in antibiotic-associated diarrhoea. Aliment Pharmacol Ther. 2012;35:1355-69.
55. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol. 2006;101(4):812-22.
56. Hempel S, Newberry SJ, Maher AR, Wang Z, Miles JN, Shanman R, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012;307(18):1959-69.
57. Gao X W, Mubasher M, Fang CY, Reifer C, Miller LE. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol. 2010;105:1636-41.
58. Pillai A, Nelson RL. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev. 2008;(1):CD004611.
59. Borody TJ, Campbell J. Fecal microbiota transplantation: current status and future directions. Expert Rev Gastroenterol Hepatol. 2011;5(6):653-5.
60. Deshpande G, Rao S, Patole S,Bulsara M. Updated meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates. Pediatrics. 2010;125:921-30.
61. Lin HC, Su BH, Chen AC, Lin TW, Tsai CH, Yeh TF, et al. Oral probiotics reduce the incidence and severity of necrotiz-ing enterocolitis in very low birth weight infants. Pediatrics. 2005;115(1):1-4.
62. Bin-Nun A, Bromiker R, Wilschanski M, Kaplan M, Rudensky B, Caplan M, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates. J Pediatr. 2005;147:192-6.
63. Lin HC, Hsu CH, Chen HL, Chung My, Hsu JF, Lien RI, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants: a multicenter, randomized, controlled trial. Pediatrics. 2008;122(4):693-700.
64. Stratiki Z, Costalos C, Sevastiadou S, Kastanidou O, Skouroliakou M, Giakoumatou A, et al. The effect of a bifidobacter supplemented bovine milk on intestinal perme-ability of preterm infants. Early Hum Dev. 2007;83(9):575-9.
65. Rougé C, Piloquet H, Butel MJ, Berger B, Rochat F, Ferraris L, et al. Oral supplementation with probiotics in very low-birth-weight preterm infants: a randomized, double blind, placebo-controlled trial. Am J Clin Nutr. 2009;89(6):1828-35.
66. Manzoni P, Rinaldi M, Cattani S, Pugni L, Romeo MG, Messner H, et al. Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial. JAMA. 2009;302:1421-8.
67. Braga TD, Pontes da Silva GA, Cabral de Lira PI, de Carvalho Lima M. Efficacy of Bifidobacterium breve and Lactobacillus casei oral supplementation on necrotizing enterocolitis in very-low-birth-weight preterm infants: a double-blind, randomized, controlled trial. Am J Clin Nutr. 2011;93(1):81-6.
68. Mihatsch WA, Braegger CP, Decsi T, Kolacek S, Lanzinger H, Mayer B, et al. Critical systematic review of the level of evidence for routine use of probiotics for reduction of mortality and prevention of necrotizing enterocolitis and sepsis in preterm infants. Clin Nutr. 2012;31:6-15.
69. Deshpande GC, Rao SC, Keil AD, Patole SK. Evidence-based guidelines for use of probiotics in preterm neonates. BMC Med. 2011;9:92.
70. AlFaleh K, Anabrees J, Bassler D, Al-Kharfi T. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev. 2011;(3):CD005496.
71. Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, et al.; on behalf of the IBD Section of the British Society of Gastroenterology. Guidelines for the management of inflam-matory bowel disease in adults. Gut. 2011;60(5):571-607.
72. Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol. 2009;104:437-43.
73. Huynh HQ, deBruyn J, Guan L, Diaz H, Li M, Girgis S, et al. Probiotic preparation (VSL#3) induces remission in children with mild to moderate acute ulcerative colitis: a pilote study. Inflamm Bowel Dis. 2009;15:760-8.
74. Sood A, Midha V, Makharia GK, Ahuja V, Singal D, Goswami P, et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7:1202-9.
75. Tursi A, Brandimarte G, Papa A, Giglio A, Elisei W, Giorgetti GM, et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind randomized, pla-cebo-controlled study. Am J Gastroenterol. 2010;105(10): 2218-27.
76. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119:305-9.
77. Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004;53:108-14.
78. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, et al. Prophylaxis of pouchitis onset with pro-biotic therapy: a double-blind, placebo-controlled trial. Gastroenterology. 2003;124:1202-9.
79. Gosselink MP, Schouten WR, van Lieshout LM, Hop WC, Laman JD, Ruseler-van Embden JG. Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum. 2004;47(6):876-84.
80. Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised con-trolled trial with Lactobacillus GG. Gut. 2002;51:405-9.
81. Marteau P, Lémann M, Seksik P, Laharie D, Colombel JF, Bouhnik Y, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut. 2006;55(6):842-7.
82. Schultz M, Timmer A, Herfarth HH, Sartor RB, Vanderhoof JA, Rath HC. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol. 2004;4:5.
83. Campieri M, Rizzello F, Venturi A. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: a randomised controlled study vs mesalamine. Gastroenterology. 2000; 118:A4179.
84. Nobaek S, Johansson ML, Molin G, Ahrne S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol. 2000;95:1231-8.
85. Niedzielin K, Kordecki H, Birkenfeld B. A controlled, doubleblind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2001;13:1143-7.
86. Halpern GM, Prindiville T, Blankenburg M, Hsia T, Gershwin ME. Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double-blind, cross over trial. Am J Gastroenterol. 1996;91:1579-85.
87. O'Mahony L, Mccarthy J, Kelly P, Hurley G, Luo F, Chen K, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128(3):541-51.
88. Guarner F, Khan AC, Garisch J, Eliakim R, Gangl A, Thomson A, et al. WGO Practice Guideline probiotics and prebiotics. Milwaukee (WI): WGO; 2008.
89. American College of Gastroenterology. An evidence-based systematic review on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104:S1-35.
90. McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol. 2008;14:2650-61.
91. NICE clinical guideline 61: Irritable bowel syndrome in adults. 2008. London: NICE. Available from: http://www.nice.org.uk/ Accessed date: April 5, 2012.
92. Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O'Mahony L, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006;101(7):1581-90.
93. Kajander K, Hatakka K, Poussa T, Farkkila M, Korpela R. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther. 2005;22:387-94.
94. Boyle RJ, Bath-Hextall FJ, Leonardi-Bee J, Murrell DF, Tang ML. Probiotics for treating eczema. Cochrane Database Syst Rev. 2008;(4):CD006135.
95. Kocourková I, Zádníkováa R, Zižkab J, Rosovác E. coli strain on the intestinal microflora of children of allergic mothers during the first year of life V. Effect of oral application of a probiotic Folia Microbiol. 2007;52:189-93.
96. Wickens K, Black PN, Stanley TV, Mitchell E, Fitzharris P, Tannock GW, et al. Probiotic Study Group. A differential effect of 2 probiotics in the prevention of eczema and atopy: a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2008;122:788-94.
97. Kalliomäki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet. 2001;357(9262):1076-9.
98. Kalliomäki M, Salminen S, Poussa T, Arvilommi H, Isolauri E. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet. 2003;361(9372):1869-71.
99. Kalliomäki M, Salminen S, Poussa T, Isolauri E. Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2007;119:1019-21.
100. Kopp MV, Goldstein M, Dietschek A, Sofke J, Heinzmann A, Urbanek R. Lactobacillus GG has in vitro effects on enhanced interleukin-10 and interferon-gamma release of mononuclear cells but no in vivo effects in supplemented mothers and their neonates. Clin Exp Allergy. 2008;38:602-10.
101. Rautava S, Arvilommi H, Isolauri E. Specific probiotics in enhancing maturation of IgA responses in formula-fed infants. Pediatr Res. 2006;60(2):221-4.
102. Soh SE, Aw M, Gerez I, Chong YS, Rauff M, Ng YP, et al. Probiotic supplementation in the first 6 months of life in at risk Asian infants - effects on eczema and atopic sensitization at the age of 1 year. Clin Exp Allergy. 2009;39(4):571-8.
103. Huurre A, Kalliomäki M, Rautava S, Rinne M, Salminen S, Isolauri E. Mode of delivery - effects on gut microbiota and humoral immunity. Neonatology. 2008;93(4):236-40.
104. Kuitunen M, Kukkonen K, Juntunen-Backman K, Korpela R, Poussa T, Tuure T, et al. Probiotics prevent IgE-associated allergy until age 5 years in cesarean-delivered children but not in the total cohort. J Allergy Clin Immunol. 2009;123(2): 335-41.
105. West CE, Hammarström ML, Hernell O. Probiotics during weaning reduce the incidence of eczema. Pediatr Allergy Immunol. 2009;20(5):430-7.
106. Abrahamsson TR, Jakobsson T, Böttcher MF, Fredrikson M, Jenmalm MC, Björkstén B, et al. Probiotics in prevention of IgE-associated eczema: a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2007;119:1174-80.
107. Schiffrin EJ, Rochat F, Link-Amster H, Aeschlimann JM, Donnet-Hughes A. Immunomodulation of human blood cells following the ingestion of lactic acid bacteria. J Dairy Sci. 1995;78:491-7.
108. Parra MD, Martinez de Morentin, BE, Cobo JM, Mateos A, Martinez JA. Daily ingestion of fermented milk containing Lactobacillus casei DN114001 improves innate-defense capa-city in healthy middle-aged people. J Physiol Biochem. 2004;60:85-91.
109. Olivares M, Diaz-Ropero MP, Gomez N, Lara-Villoslada F, Sierra S, Maldonado JA, et al. The consumption of two new probiotic strains, Lactobacillus gasseri CECT 5714 and Lactobacillus coryniformis CECT 5711, boosts the immune system of healthy humans. Int Microbiol. 2006;9:47-52.
110. de Vrese M, Winkler P, Rautenberg P, Harder T, Noah C, Laue C, et al. Probiotic bacteria reduced duration and severity but not the incidence of common cold episodes in a double blind, randomized, controlled trial. Vaccine. 2006;24(44-46):6670-74.
111. Winkler P, de Vrese M, Laue Ch, Schrezenmeir J. Effect of a dietary supplement containing probiotic bacteria plus vitamins and minerals on common cold infections and cellular immune parameters. Int J Clin Pharmacol Ther. 2005;43:318-26.
112. Lin JS, Chiu YH, Lin NT, Chu CH, Huang KC, Liao KW, et al. Different effects of probiotic species/strains on infections in preschool children: a double-blind, randomized, controlled study. Vaccine. 2009;27(7):1073-9.
113. Biagi E, Candela M, Fairweather-Tait S, Franceschi C, Brigidi P. Ageing of the human metaorganism: the microbial counter-part. Age (Dordr). 2012;34(1):247-67.
114. Bartosch S, Fite A, Macfarlane GT, McMurdo ME. Characterization of bacterial communities in feces from healthy elderly volunteers and hospitalized elderly patients by using real-time PCR and effects of antibiotic treatment on the fecal microbiota. Appl Environ Microbiol. 2004;70:3575-81.
115. Woodmansey EJ. Intestinal bacteria and aging. J Appl Microbiol. 2007;102:1178-86.
116. Franceschi C, Monti D, Sansoni P, Cossarizza L. The immunology of individuals: the lesson of centenarians. Immunol Today. 1995;16:12-6.
117. Goodwin JS. Decreased immunity and increased morbidity in the elderly. Nutr Rev. 1995;53:S41-5.
118. Gill HS, Rutherfurd KJ. Viability and dose-response studies on the effects of the immunoenhancing lactic acid bacterium Lactobacillus rhamnosus in mice. Br J Nutr. 2001;86:285-9.
119. Arunachalam K, Gill HS, Chandra RK. Enhancement of natural immune function by dietary consumption of Bifidobacterium lactis (HN019). Eur J Clin Nutr. 2000;54:263-7.
120. Sheih YH, Chiang BL, Wang LH, Liao CK, Gill HS. Systemic immunity-enhancing effects in healthy subjects following dietary consumption of the lactic acid bacterium Lactobacillus rhamnosus HN001. J Am Coll Nutr. 2001;20:149-56.
121. Ibrahim F, Ruvio S, Granlund L, Salminen S, Viitanen M, Ouwehand AC. Probiotics and immunosenescence: cheese as a carrier. FEMS Immunol Med Microbiol. 2010;59(1):53-9.
122. Mikelsaar M, Zilmer M. Lactobacillus fermentum ME-3 - an antimicrobial and antioxidative probiotic. Microb Ecol Health Dis. 2009;21(1):1-27.
123. Plummer S, Weaver MA, Harris JC, Dee P, Hunter J. Clostridium difficile pilot study: effects of probiotic supple-mentation on the incidence of C. difficile diarrhoea. Int Microbiol. 2004;7:59-62.
124. Zaharoni H, Rimon E, Vardi H, Friger M, Bolotin A, Shahar DR. Probiotics improve bowel movements in hospitalized elderly patients - the PROAGE study. J Nutr Health Aging. 2011;15(3):215-20.
125. Hatakka K, Ahola AJ, Yli-Knuuttila H, Richardson M, Poussa T, Meurman JH, et al. Probiotics reduce the prevalence of oral Candida in the elderly - a randomized controlled trial. J Dent Res. 2007;86:125-30.
126. Johansson ML, Molin G, Jeppsson B, Nobaek S, Ahrné S, Bengmark S. Administration of different Lactobacillus strains in fermented oatmeal soup: in vivo colonization of human intestinal mucosa and effect on the indigenous flora. Appl Environ Microb. 1993;59:15-20.
127. Firmesse O, Mogenet A, Bresson JL, Corthier G, Furet JP. Lactobacillus rhamnosus R11 consumed in a food supplement survived human digestive transit without modifying micro-biota equilibrium as assessed by real-time polymerase chain reaction. J Mol Microbiol Biotechnol. 2008;14(1-3):90-9.
128. Dommels YE, Kemperman RA, Zebregs YE, Draaisma RB, Jol A, Wolvers DA, et al. Survival of Lactobacillus reuteri DSM 17938 and Lactobacillus rhamnosus GG in the human gastrointestinal tract with daily consumption of a low-fat probiotic spread. Appl Environ Microbiol. 2009;75:6198-204.
129. Gianotti L, Morelli L, Galbiati F, Rocchetti S, Coppola S, Beneduce A, et al. A randomized double-blind trial on perioperative administration of probiotics in colorectal cancer patients. World J Gastroenterol. 2010;16(2):167-75.
130. Larsen CN, Nielsen S, Kaestel P, Brockmann E, Bennedsen M, Christensen HR, et al. Dose-response study of probiotic bacteria Bifidobacterium animalis subsp lactis BB-12 and Lactobacillus paracasei subsp paracasei CRL-341 in healthy young adults. Eur J Clin Nutr. 2006;60:1284-93.
131. Sullivan A, Bennet R, Viitanen M, Palmgren AC, Nord CE. Influence of Lactobacillus F19 on intestinal microflora in children and elderly persons and impact on Helicobacter pylori infections. Microb Ecol Health Dis. 2002;14(1):17-21.
132. Collins JK, Dunne C, Murphy L, Morrissey D, O'Mahony L, O'Sullivan E, et al. A randomized controlled trial of a probiotic Lactobacillus strain in healthy adults: assessment of its delivery, transit and influence on microbial flora and enteric immunity. Microb Ecol Health Dis. 2002;14:81-9.
133. Pochart P, Marteau P, Bouhnik Y, Goderel I, Bourlioux P, Rambaud JC. Survival of bifidobacteria ingested via fermen-ted milk during their passage through the human small intestine: an in vivo using intestinal perfusion. Am J Clin Nutr. 1992;55:78-80.
134. Pochart P, Dewit O, Desjeux JF, Bourlioux P. Viable starter culture, beta-galactosidase activity, and lactose in duodenum after yogurt ingestion in lactase-deficient humans. Am J Clin Nutr. 1989;49(5):828-31.
135. Blehaut H, Massot J, Elmer GW, Levy RH. Disposition kinetics of Saccharomyces boulardii in man and rat. Biopharm Drug Dispos. 1989;10:353-64.
136. McFarland LV, Bernasconi P. Saccharomyces boulardii: a review of an innovative bioterapeutic agent. Microb Ecol Health Dis. 1993;6:157-71.
137. Vanderhoof JA, Whitney DB, Antonson DL, Hanner TL, Lupo JV, Young RJ. Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. J Pediatr. 1999;135(5):564-8.
138. Arvola T, Laiho K, Torkkeli S, Mykkanen H, Salminen S, Maunula L, et al. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. Pediatrics. 1999;104(5):e64
139. LaRosa M, Bottaro G, Gulino N, Gambuzza F, Di Forti F, Ini G, et al. Prevention of antibiotic-associated diarrhea with Lactobacillus sporogens and fructo-oligosaccharides in chil-dren: a multicentric double-blind vs placebo study. Minerva Pediatr. 2003;55(5):447-52.
140. Benhamou PH, Berlier P, Danjou G, Plique O, Jessueld D, DuPont C. Antibiotic-associated diarrhoea in children: a computer monitored double-blind outpatients trial comparing a protective and a probiotic agent. Med Chir Dig. 1999;28(4):163-8.
141. Erdeve O, Tiras U, Dallar Y. The probiotic effect of Saccharomyces boulardii in a pediatric age group. J Trop Pediatr. 2004;50(4):234-6.
142. Kotowska M, Albrecht P, Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Alimentar Pharmacol Ther. 2005;21:583-90.
143. Contardi I. Oral bacteria therapy in prevention of antibiotic-induced diarrhea in childhood. Clin Ter. 1991;136(6):409-13.
144. Correa NB, Peret Filho LA, Penna FJ, Lima FM, Nicoli JR. A randomized formula controlled trial of Bifidobacterium lactis and Streptococcus thermophilus for prevention of antibiotic-associated diarrhea in infants. J Clin Gastroenterol. 2005; 39(5):385-9.
145. Tankanow RM, Ross MB, Ertel IJ, Dickinson DG, McCormick LS, Garfinkel JF. A double-blind, placebo-controlled study of the efficacy of Lactinex in the prophylaxis of amoxicillin-induced diarrhea. DICP. 1990;24(4):382-4.
146. Huang JS, Bousvaros A, Lee JW, Diaz A, Davidson EJ. Efficacy of probiotic use in acute diarrhea in children: a meta-analysis. Dig Dis Sci. 2002;47:2625-34.
147. Szajewska H, Mrukowicz JZ. Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials. J Pediatr Gastroenterol Nutr. 2001;33(Suppl 2):S17-25.
148. Stansbridge EM, Walker V, Hall MA, Smith SL, Millar MR, Bacon C, et al. Effects of feeding premature neonates with Lactobacillus GG on gut fermentation. Arch Dis Child. 1993;69:488-92.
149. Millar MR, Bacon C, Smith SL, Walker V, Hall MA. Enteral feeding of premature neonates with Lactobacillus GG. Arch Dis Child. 1993;69:483-7.
150. Kitajima H, Sumida Y, Tanaka R, Yuki N, Takayama H, Fujimura M. Early administration of Bifidobacterium breve to preterm neonates: randomised control trial. Arch Dis Child. 1997;76:F101-7.
151. Costalos C, Skouteri V, Gounaris A, Sevastiadou S, Triandafilidou A, Ekonomidou C, et al. Enteral feeding of premature neonates with Saccharomyces boulardii. Early Hum Dev. 2003;74:89-96.
152. Manzoni P, Mostert M, Leonessa ML, Priolo C, Farina D, Monetti C, et al. Oral supplementation with Lactobacillus casei subspecies rhamnosus prevents enteric colonisation by Candida species in preterm neonates: a randomised study. Clin Infect Dis. 2006;42:1735-42.
153. Mohan R, Koebnick C, Schildt J, Schmidt S, Mueller M, Possner M, et al. Effects of Bifidobacterium lactis Bb12 supplementation on intestinal microbiota of preterm neonates: a double placebo controlled, randomised study. J Clin Microbiol. 2006;44:4025-31.
154. Sari FN, Dizdar EA, Oguz S, Erdeve O, Uras N, Dilmen U. Oral probiotics: Lactobacillus sporogenes for prevention of necrotizing enterocolitis in very low-birth weight infants: a randomized, controlled trial. Eur J Clin Nutr. 2011;65: 434-9.
155. Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr. 2003;22:56-63.
156. Kato K, Mizuno S, Umesaki Y, Ishii Y, Sugitani M, Imaoka A, et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther. 2004;20:1133-41.
157. Tursi A, Brandimarte G, Giorgetti GM, Forti G, Modeo ME, Gigliobianco A. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit. 2004;10: PI126-31.
158. Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol. 2005;100:1539-46.
159. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 1999;354:635-9.
160. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli prepara-tion and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 1997;11:853-8.
161. Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, Kascak M, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004;53:1617-23.
162. Laake KO, Line PD, Grzyb K, Aamodt G, Aabakken L, Roset A, et al. Assessment of mucosal inflammation and blood flow in response to four weeks' intervention with probiotics in patients operated with a J-configurated ileal-pouch-anal-anastomosis (IPAA). Scand J Gastroenterol. 2004;39:1228-35.
163. McCarthy J, O'Mahony L, Dunne C. An open trial of a novel probiotic as an alternative to steroids in mild/moderately active Crohn's disease. Gut. 2001;49(Suppl III):A2447.
164. Malchow HA. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol. 1997;25:653-8.
165. Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci. 2000;45(7):1462-4.
166. van Gossum A, Dewit O, Louis E, de Hertogh G, Baert F, Fontaine F et al. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after ileo-caecal resection. Inflamm. Bowel Dis. 2007;13:135-42.
167. Chermesh I, Tamir A, Reshef R, Chowers Y, Suissa A, Katz D, et al. Failure of Synbiotic 2000 to prevent postopera-tive recurrence of Crohn's disease. Dig Dis Sci. 2007;52: 385-9.
168. O'Sullivan M, O'Morain C. Bacterial supplementation in the irritable bowel syndrome: a randomized double-blind placebo controlled crossover study. Dig Liver Dis. 2000;32:294-301.
169. Simren M, Syrous A, Lindh A, Abrahamsson H. Effects of Lactobacillus plantarum 299V on symptoms and rectal sensitivity in patients with irritable bowel syndrome (IBS) - a randomized double blind controlled trial. Gastroenterology. 2006;130(Suppl 2):A600.
170. Niv E, Naftali T, Hallak R, Vaisman N. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome-a double blind, placebo-controlled, randomized study. Clin Nutr. 2005;24:925-31.
171. Sinn DH, Song JH, Kim HJ, Lee JH, Son HJ, Chang DK, et al. Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig Dis Sci. 2008;53:2714-8.
172. Kim HJ, Camilleri M, McKinzie S, Lempke MB, Burton DD, Thomforde GM, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2003;17(7):895-904.
173. Williams E, Stimpson J, Wang D, Plummer S, Garaiova I, Barker M, et al. Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2009;29(1):97-103.
174. Drouault-Holowacz S, Bieuvelet S, Burckel A, Cazaubiel M, Dray X, Marteau P. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Gastroenterol Clin Biol. 2008;32:147-52.
175. Simrén M, Ohman L, Olsson J, Svensson U, Ohlson K, Posserud I, et al. Clinical trial: the effect of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome (IBS) - a randomized, double-blind, controlled study. Aliment Pharmacol Ther. 2010;31:218-27.